白血病抑制因子受体与白血病细胞U937内促分裂原活化蛋白激酶的关系

探讨人白血病细胞系U937白血病抑制因子 (LIF)受体α亚基和另一亚基gp130细胞内区与促分裂原活化蛋白激酶 (MAPK)的关系 ,旨在研究白血病细胞增殖和分化的机制。用基因重组技术将两基因细胞内区互换以构成两嵌合体受体 (190 130 ,130 190 )并分别在U937表达 ,其与野生受体竞争性结合白血病抑制因子 ,用免疫组化和免疫印迹法分析受体细胞内区形成同源性二聚体(190cyt 190cyt,130cyt 130cyt)后的细胞状况和细胞内MAPK的水平。结果表明 ,转染pE190 130后用LIF作用 6h ,U937细胞MAPK表达量增加 ,MAPK形成的二聚体较明显 ,细胞增殖较快 ;而另一嵌合体受体与α亚基形成 190cyt 190cyt时U937细胞MAPK的表达无变化 ,二聚体不明显。说明LIF受体中gp130亚基的细胞内区参与了MAPK的激活及白血病U937细胞增殖信号的传递。     

190CT3多肽调节白血病细胞增殖分化的实验研究

白血病抑制因子（LIF）是一种多效性细胞因子,作用于多种细胞组织发挥不同的生物学作用。其生物学效应依赖于其结合靶细胞膜上的LIF受体a亚基（gp190）,与8亚基（gp130）形成异源性二聚体,从而激活下游信号转导通路。LIF因子可通过激活JAK-STAT和RAS-MAPK途径,调节白血病细胞的增殖分化。我们根据gp190细胞内区功能域设计了小分子-190CT3,     

CD真核表达载C 体的构建及在 2KHE39 细胞中的表达

目的：构建含自杀基因胞嘧啶脱氨酶（CD）的真核表达载体pcDNA3．1／HA—myc-His（-）Z—CD,并进行哺乳动物细胞HEK293转染研究。方法：以本实验室保存的含CD基因全长的质粒为模版,用PcR方法扩增CD基因阅读框序列,并定向克隆到带有HAtag的pcDNA3．1／HA—myc-His（-）Z载体上,使目的基因与HAtag在同一阅读框。重组体质粒经EcoRI和BamHI双酶切鉴定,并对插入的CD基因片段进行测序,将鉴定好的阳性重组质粒pcDNA3．1／HA—myc-His（-）Z—CD用脂质体介导转染HEK293,提取细胞蛋白,western blot检测CD基因的表达情况.结果：阳性重组质粒pcDNA3．1／HA—myc-His（-）ZCD经Eco砌和BanHI双酶切后,获得约为5．5kb片段和1．3kb插入片段,序列分析表明插入的片段与GenBank发布的序列一致．western blot检测到CD基因的表达。结论：成功构建了含自杀基因CD的真核表达质粒。     

反义CD151基因转染对大鼠血管平滑肌细胞迁移的影响

目的观察pcDNA3.1真核表达载体介导的反义CD151基因转染对培养的大鼠动脉平滑肌细胞(VSMCs)迁移的影响。方法构建携带全长正义和反义CD151的真核表达载体pcDNA3.1-CD151和pcDNA3.1-anti-CD151重组质粒,转染体外培养的VSMCs,以RT-PCR和Western blot方法检测CD151的表达,用Boyden趋化小室方法观察细胞迁移。结果与载体对照组、脂质体对照组和空白对照组3组均值比较,转染48h后,反义CD151组mRNA表达降低58%,蛋白表达降低51%,正义CD151组的VSMCs CD151mRNA表达增加171%,蛋白表达增加133%;趋化迁移的细胞数,反义CD151组为37.9±6.3,正义CD151组为86.5±12.4;载体对照组、脂质体对照组和空白对照组分别为60.3±7.1、61.8±7.6和67.3±9.6。反义CD151组显著低于其余各组(P<0.01),正义CD151组显著高于其余各组(P<0.01)。结论pcDNA3.1真核表达载体介导的反义CD151转染,通过抑制CD151的表达,能够显著抑制大鼠VSMCs的迁移。     

CD59、CD55在T细胞活化信号转导中的协同作用

目的：研究糖基磷脂酰肌醇（GeD）锚固蛋白CD59、CD55在脂筏介导T细胞信号转导通路中的协同效应。方法：应用siRNA技术,构建特异性针对CD55与CD59基因的重组载体pSUPER—siCD55,pSUPER—siCD59。实验分为未转染的Jurkat细胞组（I组）、转染pSUPER空质粒的Jurkat细胞组（Ⅱ组）、转染pSUPER—siCD59重组质粒的Jurkat细胞组（Ⅲ组）及转染pSUPER—siCD55重组质粒的Jurkat细胞组（Ⅳ组）。RT—PCR检测转染细胞中CD55和CD59基因的表达。噻唑蓝（MTT）比色法和激光共聚焦扫描显微镜分别检测CD55与CD59联合作用对4组Jurkat细胞的增殖效应以及细胞内钙离子的变化。结果：稳定转染后,Ⅲ组细胞CD59分子的表达和Ⅳ组细胞CD55分子的表达被成功抑制。Ⅰ组和Ⅱ组细胞CD55与CD59联合作用后增殖能力和钙离子浓度均明显高于Ⅲ组、Ⅳ组（P〈0．05）,Ⅰ组和Ⅱ组之间无差异。结论：CD59和CD55在T细胞活化信号转导通路中存在协同效应。     

CD59、CD55在T细胞活化信号转导中的协同作用

目的:研究糖基磷脂酰肌醇(GPI)锚固蛋白CD59、CD55在脂筏介导T细胞信号转导通路中的协同效应。方法:应用siRNA技术,构建特异性针对CD55与CD59基因的重组载体pSUPER-siCD55,pSUPER-siCD59。实验分为未转染的Jurkat细胞组(Ⅰ组)、转染pSUPER空质粒的Jurkat细胞组(Ⅱ组)、转染pSUPER-siCD59重组质粒的Jurkat细胞组(Ⅲ组)及转染pSUPER-siCD55重组质粒的Jurkat细胞组(Ⅳ组)。RT-PCR检测转染细胞中CD55和CD59基因的表达噻唑蓝(MTT)比色法和激光共聚焦扫描显微镜分别检测CD55与CD59联合作用对4组Jurkat细胞的增殖效应以及细胞内钙离子的变化、结果:稳定转染后,Ⅲ组细胞CD59分子的表达和Ⅳ组细胞CD55分子的表达被成功抑制。Ⅰ组和Ⅱ组细胞CD55与CD59联合作用后增殖能力和钙离子浓度均明显高于Ⅲ组、Ⅳ组(P<0.05),Ⅰ组和Ⅱ组之间无差异结论:CD59和CD55在T细胞活化信号转导通路中存在协同效应。     

血源细胞系中CD39的表达和功能分析

细胞外ATP通过激活细胞膜上核苷酸受体介导细胞间通讯。CD39是一个钙,镁离子依赖的ATP双磷酸酶,其对ATP信号的调节机制尚未完全阐明。采用半定量RT．PCR、ABC免疫酶标和流式细胞术以及荧光素／荧光素酶法,研究了七个血源细胞系中CD39的表达和功能。结果表明,不同细胞中CD39的表达水平差异显著：在J6-1和LCL-H中高水平表达,在HL60中低水平表达,而在Namalva、Jurkat,U937细胞中极低水平表达．CD39的表达与这些细胞膜上ATP酶活性、胞外ATP的基础水平结果一致,提示CD39是这些细胞膜上ATP酶活性的主要来源,可能在调节P2受体介导的细胞间通讯中起重要作用。     

CD44v6对急性白血病细胞HL-60和THP-1增殖和迁移的影响

目的:探讨CD44变异亚型对急性白血病细胞增殖和迁移的影响。方法:选择对数生长期的急性白血病细胞株HL-60、THP-1和慢性白血病细胞株K562,采用荧光定量PCR法检测CD44v6mRNA的表达。通过电转的方法转染CD44v6siRNA到HL-60和THP-1细胞抑制细胞的CD44v6表达,通过western方法检测CD44v6蛋白的抑制情况。将实验分成HL-60+N-siRNA、HL-60+CD44V6-siRNA、THP-1+N-si RNA、THP-1+CD44V6-siRNA共4组,培养24、48、72 h后分别取细胞悬液用台盼蓝染色后计数活细胞数检测细胞的增殖情况;使用Transwell小室培养法观察HL-60和THP-1细胞的迁移率。结果:通过荧光定量PCR方法检测THP-1和HL-60细胞均高表达CD44v6(分别为0.0037±0.0007和0.00292±0.0002),明显高于K562的表达(P0.01);转染后的HL-60和THP-1细胞株中CD44v6蛋白表达水平明显下调,细胞计数结果显示转染CD44v6-siRNA的HL-60和THP-1细胞在24、48和72 h增殖均明显下降。迁移实验结果显示THP-1+N-si RNA和HL-60+N-si RNA细胞的迁移率为17%和23%,与相应对照组相比THP-1+CD44v6-siRNA和HL60+CD44v6-siRNA组细胞24 h迁移率明显下降(分别降至11%和14%)。结论:CD44v6可以通过干预白血病细胞的增殖和迁移能力,参与调解白血病细胞的增殖和髓外进展。     

IL－6受体结构与功能的研究进展

IL-6是一个多功能的细胞因子,其生物学作用在很大程度上受IL-6受体(IL-6R)结构和功能的影响.IL-6R由两条多肽链组成,即配体结合链gp80和信号传导链gp130.它们在结构和功能上既有分工又有合作.两种亚基组成的高亲和力IL-6R是介导细胞效应所必需的.IL-6Rα中的造血功能区属于造血因子受体超家族成员,它决定着结合IL-6的能力.然而gp130则是多种细胞因子共用的信号传递分子,其胞内段含有与酪氨酸激酶活化有关的保守成分.IL-6+IL-6R复合物通过诱导gp130的聚合来活化胞内的多种激酶分子和转录因子并最终导致有关基因的表达.     

Mac-1-FP融合表达载体的构建、Mac-1-FP的表达与活性鉴定

分别构建表达BFP与CD1 1b的C末端、YFP与CD1 8的N末端相连接的融合蛋白的表达载体 ,并将二者转染至既无内源性Mac 1的表达同时又具有某些炎症反应信号转导系统的CHO细胞株进行表达Mac 1 FP .通过荧光显微镜观察到共转染后的CHO细胞可发出蓝色荧光和黄色荧光 ,应用Western印迹方法确定CD1 1b BFP与YFP CD1 8能够形成二聚体 ,采用流式细胞术检测确定PMA刺激Mac 1 FP可由胞浆内转位至膜上 ,测定PMA刺激前后的转染CHO细胞与其配基ICAM 1粘附活性的变化 ,证明转染CHO中的Mac 1 FP表达成功并具有野生型Mac 1的形成二聚体、膜转位、和配基ICAM 1相结合等功能 ,为进一步研究白细胞表面粘附分子Mac 1的α亚基CD1 1b、β亚基CD1 8在细胞内的走向及归宿创造了条件     

Involving of the cytoplasmic region of leukemia inhibitory factor receptor α subunit,IL-6 related signal transducer-gp130 or Fas death domain for MAPK p42/44 activation in HL-60 cell with LIF or anti-Fas IgG

The chimeric receptors were prepared by exchanging the cytoplasmic region between leukemia inhibitory factor (LIF) receptor subunit (gp190) and the other subunit-gp130 (190/130,130/190) and separately transduced into leukemia line HL-60 (to have the wild type subunit). The purpose is to investigate which subunit for activating MAPK p42/44 in leukemia cell while the cytoplasmic region homodimerization (190cyt-190cyt, 130cyt-130cyt) was induced by LIF. The results showed that MAPK p42/44 expression level after LIF stimulation 5 h was lower in the transformants with pED 130/190 (190cyt-190cyt) (p < 0.01) and higher in the transformants with pED 190/130 (130cyt-130cyt) (p < 0.05) than those in the parent cells. Meanwhile, MAPK p42/44 phosphorylation (Thr202/Tyr204) was ascended and the highest at 10 min in the 190/130 and descended in the 130/190. It suggests that gp130 activate MAPK p42/44 and gp190 indirectly regulate its expression and function. In order to analyses the relation of the subunit oligomerization and MAPK p42/44 we also prepared the recombination of the extracellular and transmembrane region of Fas and the cytoplasmic region of each LIFR subunit (Fas/190, Fas/130). After transduction into HL-60 with lipofection and induction by anti-Fas IgG, we found that MAPK p42/44 expression levels were lower in the Fas/190 than in the Fas/130 and parent cells (p < 0.01) and no difference between the Fas/130 and the wild type receptor. However, phospho-MAPK p42/44 were increased in the Fas/130 than the parent cells. It suggests that the oligomerization of the cytoplasmic regions of gp130 be potential to normally initiate MAPK p42/44 for the signal of HL-60 proliferation. We also determine that the separated oligomerization FasDD (no dimerization) can initiate the corresponding signal molecules, then regulate MAPK p42/44 expression and phosphorylation in leukemia cells.     

STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells.

Embryonic stem (ES) cells can be maintained in an undifferentiated state in the presence of leukemia inhibitory factor (LIF). LIF acts through a receptor complex composed of a low affinity LIF receptor (LIFRbeta) and gp130. We reported that the intracellular domain of gp130 plays an important role in self-renewal of ES cells. In the present study, we examined the signaling pathway through which gp130 contributes to the self-renewal of ES cells. Mutational analysis of the cytoplasmic domain of gp130 revealed that the tyrosine residue of gp130 responsible for STAT3 activation is necessary for self-renewal of ES cells, while that required for SHP2 and MAP kinase activation was dispensable. Next, we constructed a fusion protein composed of the entire coding region of STAT3 and the ligand binding domain of the estrogen receptor. This construction (STAT3ER) induced expression of junB (one of the targets of STAT3) in ES cells in the presence of the synthetic ligand 4-hydroxytamoxifen (4HT), thereby indicating that STAT3ER is a conditionally active form. ES cells transfected with STAT3ER cultured in the presence of 4HT maintained an undifferentiated state. Taken together, these results strongly suggest that STAT3 activation is required and sufficient to maintain the undifferentiated state of ES cells.     

Mutations in the immunoglobulin-like domain of gp190, the leukemia inhibitory factor (LIF) receptor,increase or decrease its affinity for LIF

The leukemia inhibitory factor (LIF) receptor comprises the low affinity binding chain gp190 and the high affinity converter gp130. The ectodomain of gp190 is among the most complex in the hematopoietin receptor family, because it contains two typical cytokine receptor homology domains separated by an immunoglobulin-like (Ig-like) domain. Human and murine gp190 proteins share 76% homology, but murine gp190 binds human LIF with a much higher affinity, a property attributed to the Ig-like domain. Using alanine-scanning mutagenesis of the Ig-like domain, we mapped a LIF binding site at its carboxyl terminus, mainly involving residue Phe-328. Mutation of selected residues into their orthologs in the murine receptor (Q251E and N321D) significantly increased the affinity for human LIF. Interestingly, these residues, although localized at both the amino and carboxyl terminus, make a spatially unique LIF binding site in a structural model of the Ig-like module. These results demonstrate definitively the role of the Ig-like domain in LIF binding and the potential to modulate receptor affinity in this family with very limited amino acid changes.     

Identification of a gp130 cytokine receptor critical site involved in oncostatin M response

Gp130 cytokine receptor is involved in the formation of multimeric functional receptors for interleukin-6 (IL-6), IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor, and cardiotrophin-1. Cloning of the epitope recognized by an OSM-neutralizing anti-gp130 monoclonal antibody identified a portion of gp130 receptor localized in the EF loop of the cytokine binding domain. Site-directed mutagenesis of the corresponding region was carried out by alanine substitution of residues 186-198. To generate type 1 or type 2 OSM receptors, gp130 mutants were expressed together with either LIF receptor beta or OSM receptor beta. When positions Val-189/Tyr-190 and Phe-191/Val-192 were alanine-substituted, Scatchard analyses indicated a complete abrogation of OSM binding to both type receptors. Interestingly, binding of LIF to type 1 receptor was not affected, corroborating the notion that in this case gp130 mostly behaves as a converter protein rather than a binding receptor. The present study demonstrates that positions 189-192 of gp130 cytokine binding domain are essential for OSM binding to both gp130/LIF receptor beta and gp130/OSM receptor beta heterocomplexes.     

Identification of agonistic and antagonistic antibodies against gp190, the leukemia inhibitory factor receptor, reveals distinct roles for its two cytokine-binding domains

The receptor for the cytokine leukemia inhibitory factor (LIF) associates the low affinity binding component gp190 and the high affinity converter gp130, both of which are members of the family of hematopoietic receptors characterized by the cytokine receptor homology (CRH) domain. The gp190 is among the very few members of this large family to contain two CRH domains. The membrane-distal one (herein called D1) is followed by an Ig-like domain, a membrane-proximal CRH domain called D2, and three type III fibronectin repeats. We raised a series of monoclonal antibodies specific for the human gp190. Among them was the blocking antibody 1C7, which was directed against the D1Ig region and which impaired the binding of LIF to gp190. Another blocking antibody, called 12D3, was directed against domain D2 and interfered with the reconstitution of the high affinity receptor complex, independently of the interaction between LIF and gp190. The blocking effect of these two antibodies concerned four cytokines known to use gp190, i.e. LIF, oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1. Among 23 antibodies tested alone or in combination (two anti-D2 and 21 anti-D1Ig), only the mixture of the two anti-D2 antibodies displayed agonistic activity in the absence of the cytokine. Taken together, these results demonstrate that the two CRH domains of gp190 play different functions in ligand binding and receptor activation.     

Binding Interactions of Leukemia Inhibitory Factor and Ciliary Neurotrophic Factor with the Different Subunits of Their High Affinity Receptors

Abstract: Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) share common components in their multimeric receptors. Both cytokine receptors contain gp130/interleukin-6-receptor transducer as well as gp190/low-affinity LIF receptor. For CNTF, addition of a third subunit, or α subunit, defines the high-affinity CNTF receptor. In the present study, we analyzed the binding interactions of LIF and CNTF in human cell lines and showed a mutual displacement for LIF and CNTF toward the trimeric high-affinity CNTF receptor. Similar results were obtained in the JEG cell line, which only expressed the gp130/gp190 high-affinity LIF receptor, by adding a soluble form of the αCNTF receptor to the system to reconstitute the high-affinity-type CNTF receptor. The different receptor subunits were then expressed separately in transfected cells and their binding capacities analyzed. The results showed that the heterocomplex CNTF/αCNTF receptor bound to gp130 with an affinity of 3–5 × 10⁻¹⁰ M , whereas LIF interacted mainly with gp190. In summary, the observed competition between LIF and CNTF does not result from the binding to a common site or receptor subunit, but rather to the interaction of the three receptor components to create a conformational site common to both LIF and CNTF.     

The carboxyl-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation. Involvement of STAT3

Cell type-specific responses to the leukemia inhibitory factor (LIF)/interleukin 6 cytokine family are mediated by dimerization of the LIF receptor alpha-chain (LIFRalpha) with the signal transducer gp130 or of two gp130 molecules followed by activation of the JAK/STAT and Ras/mitogen-activated protein kinase cascades. In order to dissect the contribution of gp130 and LIFRalpha individually, chimeric molecules consisting of the extracellular domain of the granulocyte colony stimulating factor receptor (GCSF-R) and various mutant forms of the cytoplasmic domains of gp130 or LIFRalpha were expressed in embryonic stem (ES) cells to test for suppression of differentiation, or in a factor-dependent plasma cytoma cell line to assess for induction of proliferation. Carboxyl-terminal domains downstream of the phosphatase (SHP2)-binding sites were dispensable for mitogen-activated protein kinase activation and the transduction of proliferative signals. Moreover, carboxyl-terminal truncation mutants which lacked intact Box 3 homology domains showed decreased STAT3 activation, failed to induce Hck kinase activity and suppress ES cell differentiation. Moreover, STAT3 antisense oligonucleotides impaired LIF-dependent inhibition of differentiation. Substitution of the tyrosine residue within the Box 3 region of the GSCF-R abolished receptor-mediated suppression of differentiation without affecting the transduction of proliferative signals. Thus, distinct cytoplasmic domains within the LIFRalpha, gp130, and GCSF-R transduce proliferative and differentiation suppressing signals.